Japan’s MHLW approves Pfizer and OPKO’s Ngenla (somatrogon), a new long-acting treatment for paediatric growth hormone deficiency

Pfizer

20 January 2022 - Ngenla offers a new once weekly treatment option for children living with growth hormone deficiency.

Pfizer and OPKO Health announced today that the next generation long-acting growth hormone injection, Ngenla (somatrogon) inj. 24 mg pens and 60 mg pens, has been approved by the Ministry of Health, Labour and Welfare in Japan. 

Ngenla is a once weekly long-acting recombinant human growth hormone, for the indication of short statue due to growth hormone deficiency without closed epiphyses.

Read Pfizer press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Paediatrics , Japan